Molecular profiling of genetic alterations in selected non-small cell lung cancer

Tiffany SY Ng, Pathmanathan Rajadurai, Yoke Kqueen Cheah


Lung cancer arises as a result of multiple genetic alterations and environmental influences such as cigarette smoking, radiation and air pollution. Molecular classification of these alterations may help in the development of individualised anticancer therapies. In this study, Ion Torrent technology was used to sequence genomic material extracted from formalin fixed paraffin embedded (FFPE) tumours. Multiple genetic variants were identified in each tumour sample. About 65% of the identified mutations occurred in the epidermal growth factor receptor (EGFR) and phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha (PIK3CA) genes. Results from this study demonstrated the feasibility of using FFPE material in next generation sequencing (NGS). In conclusion, several key mutations associated with human cancers were identified.

Full Text:

Open Access Article


Blons, H.; Pallier, K.; Le Corre, D.; Danel, C.; Tremblay-Gravel, M.; Houdayer, C.; Fabre-Guillevin, E.; Riquet, M.; Dessen, P.; Laurent-Puig, P. Genome wide SNP comparative analysis between EGFR and KRAS mutated NSCLC and characterization of two models of oncogenic cooperation in non-small cell lung carcinoma. BMC Med. Genomics 2008, 1, 25:1-25:13.

Osada, H.; Takahashi, T. Genetic alterations of multiple tumor suppressors and oncogenes in the carcinogenesis and progression of lung cancer. Oncogene 2002, 21, 7421-7434.

Reis-Filho, J. S. Next-generation sequencing. Breast Cancer Res. 2009, 11, 1-7.

Meldrum, C.; Doyle, M.; Tothill, R. Next-generation sequencing for cancer diagnostics: a practical perspective. Clin. Biochem. Rev. 2011, 32, 177-195.

Sekido, Y.; Fong, K. M.; Minna, J. D. Molecular genetics of lung cancer. Annu. Rev. Med. 2003, 54, 73-87.

Oda, K.; Matsuoka, Y.; Funahashi, A.; Kitano, H. A comprehensive pathway map of epidermal growth factor receptor signaling. Mol. Syst. Biol. 2005, 1, 1-17.

Brambilla, E.; Gazdar, A. Pathogenesis of lung cancer signalling pathways: roadmap for therapies. Eur. Respir. J. 2009, 33, 1485-1497.

Takano, T.; Ohe, Y.; Sakamoto, H.; Tsuta, K.; Matsuno, Y.; Tateishi, U.; Yamamoto, S.; Nokihara, H.; Yamamoto, N.; Sekine, I. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non–small-cell lung cancer. J. Clin. Oncol. 2005, 23, 6829-6837.

Mitsudomi, T.; Kosaka, T.; Endoh, H.; Horio, Y.; Hida, T.; Mori, S.; Hatooka, S.; Shinoda, M.; Takahashi, T.; Yatabe, Y. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non–small-cell lung cancer with postoperative recurrence. J. Clin. Oncol. 2005, 23, 2513-2520.

Paez, J. G.; Jänne, P. A.; Lee, J. C.; Tracy, S.; Greulich, H.; Gabriel, S.; Herman, P.; Kaye, F. J.; Lindeman, N.; Boggon, T. J. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304, 1497-1500.

Shigematsu, H.; Lin, L.; Takahashi, T.; Nomura, M.; Suzuki, M.; Wistuba, I. I.; Fong, K. M.; Lee, H.; Toyooka, S.; Shimizu, N. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J. Natl. Cancer Inst. 2005, 97, 339-346.

Kosaka, T.; Yatabe, Y.; Endoh, H.; Kuwano, H.; Takahashi, T.; Mitsudomi, T. Mutations of the epidermal growth factor receptor gene in lung cancer biological and clinical implications. Cancer Res. 2004, 64, 8919-8923.

Samuels, Y.; Wang, Z.; Bardelli, A.; Silliman, N.; Ptak, J.; Szabo, S.; Yan, H.; Gazdar, A.; Powell, S. M.; Riggins, G. J. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004, 304, 554-554.

Pu, X.; Hildebrandt, M. A.; Lu, C.; Lin, J.; Stewart, D. J.; Ye, Y.; Gu, J.; Spitz, M. R.; Wu, X. PI3K/PTEN/AKT/mTOR pathway genetic variation predicts toxicity and distant progression in lung cancer patients receiving platinum-based chemotherapy. Lung Cancer 2011, 71, 82-88.

Yang, F.; Tang, X.; Riquelme, E.; Behrens, C.; Nilsson, M. B.; Giri, U.; Varella-Garcia, M.; Byers, L. A.; Lin, H. Y.; Wang, J. Increased VEGFR-2 gene copy is associated with chemoresistance and shorter survival in patients with non–small-cell lung carcinoma who receive adjuvant chemotherapy. Cancer Res. 2011, 71, 5512-5521.

Krishnaswamy, S.; Kanteti, R.; Duke-Cohan, J. S.; Loganathan, S.; Liu, W.; Ma, P. C.; Sattler, M.; Singleton, P. A.; Ramnath, N.; Innocenti, F. Ethnic differences and functional analysis of MET mutations in lung cancer. Clin. Cancer Res. 2009, 15, 5714-5723.

Hunter, D. J.; Kraft, P.; Jacobs, K. B.; Cox, D. G.; Yeager, M.; Hankinson, S. E.; Wacholder, S.; Wang, Z.; Welch, R.; Hutchinson, A. A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat. Genet. 2007, 39, 870-874.

Katoh, M. Cancer genomics and genetics of FGFR2 (Review). Int. J. Oncol. 2008, 33, 233-237.

Zhang, X.; Miao, X.; Guo, Y.; Tan, W.; Zhou, Y.; Sun, T.; Wang, Y.; Lin, D. Genetic polymorphisms in cell cycle regulatory genes MDM2 and TP53 are associated with susceptibility to lung cancer. Hum. Mutat. 2006, 27, 110-117.

Soussi, T.; Béroud, C. Assessing TP53 status in human tumours to evaluate clinical outcome. Nat. Rev. Cancer 2001, 1, 233-239.

Kosaka, T.; Yatabe, Y.; Endoh, H.; Kuwano, H.; Takahashi, T.; Mitsudomi, T. Mutations of the epidermal growth factor receptor gene in lung cancer biological and clinical implications. Cancer Res. 2004, 64, 8919-8923.

Mazieres, J.; He, B.; You, L.; Xu, Z.; Jablons, D. M. Wnt signaling in lung cancer. Cancer Lett. 2005, 222, 1-10.

Shigemitsu, K.; Sekido, Y.; Usami, N.; Mori, S.; Sato, M.; Horio, Y.; Hasegawa, Y.; Bader, S. A.; Gazdar, A. F.; Minna, J. D. Genetic alteration of the β-catenin gene (CTNNB1) in human lung cancer and malignant mesothelioma and identification of a new 3p21. 3 homozygous deletion. Oncogene 2001, 20, 4249-4257.

Pao, W.; Chmielecki, J. Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat. Rev. Cancer 2010, 10, 760-774.

Carvajal, R. D.; Antonescu, C. R.; Wolchok, J. D.; Chapman, P. B.; Roman, R.; Teitcher, J.; Panageas, K. S.; Busam, K. J.; Chmielowski, B.; Lutzky, J. KIT as a therapeutic target in metastatic melanoma. JAMA 2011, 305, 2327-2334.

Robinson, J. T.; Thorvaldsdóttir, H.; Winckler, W.; Guttman, M.; Lander, E. S.; Getz, G.; Mesirov, J. P. Integrative genomics viewer. Nat. Biotechnol. 2011, 29, 24-26.

Autosomes Chromosome, X. An integrated map of genetic variation from 1,092 human genomes. Nature 2012, 491, 1.



  • There are currently no refbacks.